Plus Therapeutics Successfully Completes Key Milestone for cGMP Manufacture of Lead Investigational Radiotherapeutic (GlobeNewswire) - Jul 12, 2022 - "Plus Therapeutics...announced it has reached a key milestone on the path to commercialization of Rhenium-186 NanoLiposome (186RNL) as the Company completed the technology transfer and initiation of cGMP manufacturing of the 186RNL drug intermediate with Piramal Pharma Solutions (PPS)....'The Company has met another significant CMC milestone by having fully compliant 186RNL intermediate, and is on time and on budget to have GMP drug availability in the second half of 2022 for ongoing and planned clinical trials in adults with recurrent glioblastoma, leptomeningeal metastases and future disease targets'...'In the third quarter of 2022, we plan to issue specific guidance on feedback obtained from two FDA meetings'."
Commercial • FDA event • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor
|